BACKGROUND: It has recently been found that 5-lipoxygenase (5-LO) and cytochrome P450-2J2 (CYP2J2), molecules capable of arachidonic acid (AA) metabolism, might promote cancer cell viability through several mechanisms similar to those of cyclooxygenase-2 (COX-2). We found that not only COX-2 expression, but also the expression of 5-LO and CYP2J2 is up-regulated in head and neck squamous cell carcinoma (HNSCC) cell lines. From these observations, we hypothesized that AA metabolism by 5-LO and/or CYP2J2 may lower the efficacy of anti-cancer effect by COX-2 inhibition. METHODS AND RESULTS: Although COX-2 was highly expressed in all cell lines tested, COX-2-specific inhibition showed little growth-inhibitory effect in some cell lines. Inhibition of COX-2 resulted in increased production of LTB(4) and 14-15-DHET/EET, metabolites of 5-LO and CYP2J2, respectively. Combined knock-down of COX-2 and 5-LO or CYP2J2 by siRNA results in a decrease in cell proliferation and VEGF production. Furthermore, these results are dependent on 5-LO and CYP2J2 expression in cells. CONCLUSION: Therefore, combined inhibition of COX-2 and 5-LO or CYP2J2 may be one way to overcome low efficacy of single inhibition of COX-2 in cancer cells. In addition, combined therapies should be chosen based on the expression of members of other AA metabolism pathways.
BACKGROUND: It has recently been found that 5-lipoxygenase (5-LO) and cytochrome P450-2J2 (CYP2J2), molecules capable of arachidonic acid (AA) metabolism, might promote cancer cell viability through several mechanisms similar to those of cyclooxygenase-2 (COX-2). We found that not only COX-2 expression, but also the expression of 5-LO and CYP2J2 is up-regulated in head and neck squamous cell carcinoma (HNSCC) cell lines. From these observations, we hypothesized that AA metabolism by 5-LO and/or CYP2J2 may lower the efficacy of anti-cancer effect by COX-2 inhibition. METHODS AND RESULTS: Although COX-2 was highly expressed in all cell lines tested, COX-2-specific inhibition showed little growth-inhibitory effect in some cell lines. Inhibition of COX-2 resulted in increased production of LTB(4) and 14-15-DHET/EET, metabolites of 5-LO and CYP2J2, respectively. Combined knock-down of COX-2 and 5-LO or CYP2J2 by siRNA results in a decrease in cell proliferation and VEGF production. Furthermore, these results are dependent on 5-LO and CYP2J2 expression in cells. CONCLUSION: Therefore, combined inhibition of COX-2 and 5-LO or CYP2J2 may be one way to overcome low efficacy of single inhibition of COX-2 in cancer cells. In addition, combined therapies should be chosen based on the expression of members of other AA metabolism pathways.
Authors: Tracy C Delozier; Grace E Kissling; Sherry J Coulter; Diana Dai; Julie F Foley; J Alyce Bradbury; Elizabeth Murphy; Charles Steenbergen; Darryl C Zeldin; Joyce A Goldstein Journal: Drug Metab Dispos Date: 2007-01-12 Impact factor: 3.922
Authors: Hong Zhu; Wayne Glasgow; Margaret D George; Kali Chrysovergis; Kenneth Olden; John D Roberts; Thomas Eling Journal: Int J Cancer Date: 2008-12-15 Impact factor: 7.396
Authors: Laleh G Melstrom; David J Bentrem; Mohammad R Salabat; Timothy J Kennedy; Xian-Zhong Ding; Matthew Strouch; Sambasiva M Rao; Richard C Witt; Charles A Ternent; Mark S Talamonti; Richard H Bell; Thomas A Adrian Journal: Clin Cancer Res Date: 2008-10-15 Impact factor: 12.531
Authors: Zora Djuric; D Kim Turgeon; Ananda Sen; Jianwei Ren; Kirk Herman; Devon Ramaswamy; Lili Zhao; Mack T Ruffin; Daniel P Normolle; William L Smith; Dean E Brenner Journal: Cancer Prev Res (Phila) Date: 2017-11-13
Authors: Anna Fishbein; Weicang Wang; Haixia Yang; Jun Yang; Victoria M Hallisey; Jianjun Deng; Sanne M L Verheul; Sung Hee Hwang; Allison Gartung; Yuxin Wang; Diane R Bielenberg; Sui Huang; Mark W Kieran; Bruce D Hammock; Dipak Panigrahy Journal: Proc Natl Acad Sci U S A Date: 2020-08-14 Impact factor: 11.205
Authors: Hannah J Gleneadie; Amy H Baker; Nikolaos Batis; Jennifer Bryant; Yao Jiang; Samuel J H Clokie; Hisham Mehanna; Paloma Garcia; Deena M A Gendoo; Sally Roberts; Megan Burley; Alfredo A Molinolo; J Silvio Gutkind; Ben A Scheven; Paul R Cooper; Joanna L Parish; Farhat L Khanim; Malgorzata Wiench Journal: Cancer Lett Date: 2021-01-05 Impact factor: 8.679
Authors: Radhakrishnan Ganesh; Daniel J B Marks; Kevin Sales; Marc C Winslet; Alexander M Seifalian Journal: World J Surg Oncol Date: 2012-09-26 Impact factor: 2.754